Cargando...
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
BACKGROUND: To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS: Observational clinical study was perfo...
Guardado en:
| Publicado en: | BMC Ophthalmol |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5442868/ https://ncbi.nlm.nih.gov/pubmed/28535756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12886-017-0471-x |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|